Syncom Formulations (India) Ltd.

₹16.89

Syncom Formulations (India) Ltd.

  • NSE : SYNCOMF
Add Alert
Add Watchlist

₹16.89

₹16.89

0.48 (2.93%) - 4 Oct 2025 04:25 PM
  • NSE : SYNCOMF

About Company

Syncom Formulations (India) Ltd. is engaged in the business of pharmaceutical formulations. The company manufactures range of products in various dosage forms and markets them in various countries. In addition to pharmaceutical formulations in the form of tablets, capsules, liquids and dry powders, the company also manufactures Injectibles, inhalers and ear/eye drops.The product range of the company includes Generic-Tablets,Capsules,Liquid Orals,Vials,Eye / Ear Drops,Ampoules and Dry Powder Orals.Herbal Branded-Colo Vaporex,Colo Inhaler,Colo Mouth Gel,Fastac Ointment,Candid Balm,Saloni Cream,Borosyn Cream,Edicare Cream,Ecziguard Cream,Pyl Gel,Attom Cream,Attom Megacaps,Shilajit Capsules,Liovset Tonic,Colo Cough Syrup,Pudin Rahat,Syncom Gripe Water,Feelax Powder and Yas Antacid Salt.Branded Allopathic-Qudermis Cream,Silver Plus Cream,Aciril Tablets,Fastac tablets,Odynil Tablets,Palera Plus Tablets,Polyfer Tablets 50 mg,Polyfer tablets 100 mg,Syncal D Tablets,M - Dox DT Tablets,Synortin Tablets,Synospas Tablets,Tici Forte Tablets,Triple Action Tablets,Flusa Kit Tablets,HBC kit (Combikit of 4 Tablets),NTB-4 Kit Tablets,Fresca Tablets,etc.

Market Cap. ₹ 1,588 Cr.
52 Week - High/Low ₹ 28/14
P/E Ratio 27.24
P/B Ratio 5.54
Enterprise Value ₹ 1,599 Cr.
ROE % 8.71
RSI Value 44.09
EMA 50 17.59
EMA 200 17.98
Market Cap. ₹ 1,588 Cr.
52 Week - High/Low ₹ 28/14
P/E Ratio 27.24
P/B Ratio 5.50
Enterprise Value ₹ 1,599 Cr.
ROE % 9.3
RSI Value 44.09
EMA 50 17.59
EMA 200 17.98

Valuation

Calculators

Peer Comparison

Industry - Pharmaceuticals & Drugs

* Please refer to the Standalone data if Consolidated financial data for the company is not available.

Shareholding Pattern Numbers in percentages

Insight market
Copyright © 2025 All rights reserved with INVESMATE INSIGHTS PRIVATE LIMITED | All logos and Trademarks registered with their respective owners.